FDA Approves Otarmeni, First Dual-AAV Gene Therapy for Severe Hearing Loss

The FDA has approved Otarmeni, a novel gene therapy targeting OTOF-related deafness, marking a historic milestone in genetic hearing loss treatment. This breakthrough offers new hope for patients with severe to profound hearing impairment and signals potential for further gene therapy advancements. Next steps include widespread clinical adoption and monitoring long-term safety and efficacy.